omniture

China-Biotics, Inc. to Present at Roth 2007 Phoenix Conference

2007-11-27 18:26 599


SHANGHAI, China, Nov. 27 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics, Inc. (OTC Bulletin Board: CHBT), a leading Chinese firm specializing in the research, development, manufacture, marketing and distribution of probiotics dietary supplements, today announced Mr. Jinan Song, the Company's Chairman and Chief Executive Officer, and Henry Tai, Vice President of Corporate Development, are scheduled to present at the Roth Capital Partners 2007 Phoenix Conference.

This two-day conference will feature presentations from management teams of more than 20 leading Chinese companies listed in the United States.

Date: Thursday, November 29, 2007

Time: 3:30 p.m. MST

Venue: The Royal Palms Resort, Phoenix, Ariz.

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand stores in major cities in China during the next two years. The Company's flagship product, "Shining Essence," was approved by the Chinese Ministry of Health for production and to market as a health product in August 2000, and it has been a profit driver since its launch in Shanghai in April 2001. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, ability to access capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

Crocker Coulson, President

CCG Elite Investor Relations

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Source: China-Biotics, Inc.
Related Stocks:
NASDAQ:CHBT
collection